1,543
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Are long-chain methotrexate polyglutamate levels the reason for LD-MTX related adverse events in inflammatory arthritis?

ORCID Icon, , &
Pages 285-287 | Received 20 Nov 2020, Accepted 28 Jan 2021, Published online: 13 Feb 2021

References

  • Solomon DH, Glynn RJ, Karlson EW, et al. Adverse effects of low-dose methotrexate: a randomized trial. Ann Intern Med. 2020;172(6):369–380.
  • Muller IB, Lin M, Struys EA, et al. Development and validation of a sensitive UHPLC-MS/MS–based method for the analysis of folylpolyglutamate synthetase enzymatic activity in peripheral blood mononuclear cells: application in rheumatoid arthritis and leukemia patients. Ther Drug Monit. 2019;41(5):598–606.
  • Sandhu A, Dhir V, Bhatnagar A, et al. High methotrexate triglutamate level is an independent predictor of adverse effects in Asian Indian rheumatoid arthritis patients-A preliminary study. Ther Drug Monit. 2017;39(2): 157–163.
  • Bajpai MCH. 1504, a metabolically inert antifolate for the potential treatment of rheumatoid arthritis. IDrugs. 2010;13(8):559–567.
  • Becker ML, Gaedigk R, van Haandel L, et al. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum. 2011;63(1):276–285.
  • Takahashi C, Kaneko Y, Okano Y, et al. Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD Open. 2017;3(1):2016–2363.
  • Brooks AJ, Begg EJ, Zhang M, et al. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther Drug Monit. 2007;29(5):619–625.
  • Ćalasan MB, den Boer E, de Rotte MC, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients. Ann Rheum Dis. 2015;74(2):402–407.
  • Muralidharan N, Sundaram R, Kodidela S, et al. Folyl polyglutamate synthethase (FPGS) gene polymorphisms may influence methotrexate adverse events in South Indian Tamil rheumatoid arthritis patients. Pharmacogenomics J. 2020;20(2):342–349.
  • Sandhu A, Dhir V, Ahmad S, et al. Clinico-genetic model to predict methotrexate intolerance in rheumatoid arthritis. Clin Rheumatol. 2020;39(1): 201–206.
  • Moya P, Salazar J, Arranz MJ, et al. Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients. Pharmacogenomics. 2016;17(1):25–29.
  • Yanagimachi M, Naruto T, Hara T, et al. Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis. Br J Clin Pharmacol. 2011;71(2):237–243.
  • Stamp LK, Barclay ML, O’Donnell JL, et al. Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol. 2011;38(12):2540–2547.
  • Dervieux T, Furst D, Lein DO, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross-sectional observational study. Ann Rheum Dis. 2005;64(8):1180–1185.
  • Becker ML, van Haandel L, Gaedigk R, et al. Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations. Arthritis Rheum. 2010;62(6):1803–1812.
  • Bujor AM, Janjua S, LaValley MP, et al. Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: A meta-analysis. PLoS One. 2019;14(9):e0221823.
  • Curtis JR, Xie F, Mackey D, et al. Patient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis. BMC Musculoskelet Disord. 2016;17(1):016–1254.
  • Hayashi K, Sada KE, Asano Y, et al. Risk of higher dose methotrexate for renal impairment in patients with rheumatoid arthritis. Sci Rep. 2020;10(1):020–75655.
  • Amin A, Effat D, Goher N, et al. Tc-99 m diethylenetriamine-pentaacetic acid (DTPA): is it reliable for assessment of methotrexate-induced cumulative effect on renal filtration in rheumatoid arthritis patients? Rheumatol Int. 2013;33(12):3059–3063.
  • Shaikh N, Sardar M, Raj R, et al. A rapidly fatal case of low-dose methotrexate toxicity. Case Rep Med. 2018 Jun 13;2018:9056086.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.